Efficacy and safety of biosimilar CT-P17 versus reference adalimumab in subjects with rheumatoid arthritis: 24-week results from a randomized study
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1478-6362
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Efficacy and safety of biosimilar CT-P17 versus reference adalimumab in subjects with rheumatoid arthritis: 24-week results from a randomized study ; volume:23 ; number:1 ; day:5 ; month:2 ; year:2021 ; pages:1-12 ; date:12.2021
Arthritis Research & Therapy ; 23, Heft 1 (5.2.2021), 1-12, 12.2021
- Creator
-
Kay, Jonathan
Jaworski, Janusz
Wojciechowski, Rafal
Wiland, Piotr
Dudek, Anna
Krogulec, Marek
Jeka, Slawomir
Zielinska, Agnieszka
Trefler, Jakub
Bartnicka-Maslowska, Katarzyna
Krajewska-Wlodarczyk, Magdalena
Klimiuk, Piotr A.
Lee, Sang Joon
Bae, Yun Ju
Yang, Go Eun
Yoo, Jae Kyoung
Furst, Daniel E.
Keystone, Edward
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s13075-020-02394-7
- URN
-
urn:nbn:de:101:1-2021032819535501833152
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 11:01 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Kay, Jonathan
- Jaworski, Janusz
- Wojciechowski, Rafal
- Wiland, Piotr
- Dudek, Anna
- Krogulec, Marek
- Jeka, Slawomir
- Zielinska, Agnieszka
- Trefler, Jakub
- Bartnicka-Maslowska, Katarzyna
- Krajewska-Wlodarczyk, Magdalena
- Klimiuk, Piotr A.
- Lee, Sang Joon
- Bae, Yun Ju
- Yang, Go Eun
- Yoo, Jae Kyoung
- Furst, Daniel E.
- Keystone, Edward
- SpringerLink (Online service)
Other Objects (12)
AVT02: An Adalimumab Biosimilar
Review of Biosimilar Trials and Data on Adalimumab in Rheumatoid Arthritis
Correction to: AVT02: An Adalimumab Biosimilar
Real-Life Tolerability and Effectiveness of Adalimumab Biosimilar in Rheumatoid Arthritis: ASPIRE Registry Data
Demonstration of Physicochemical and Functional Similarity of Biosimilar Adalimumab-aqvh to Adalimumab
Long-term efficacy, safety, and immunogenicity of the adalimumab biosimilar, PF-06410293, in patients with rheumatoid arthritis after switching from reference adalimumab (Humira®) or continuing biosimilar therapy: week 52–92 data from a randomized, double-blind, phase 3 trial
Adalimumab and anti-adalimumab LISA-TRACKER immunoassays performance criteria for therapeutic drug monitoring of adalimumab-amgen biosimilar (ABP501)
Consistency of Product Quality for SB5, an Adalimumab Biosimilar
A comparative clinical study of PF-06410293, a candidate adalimumab biosimilar, and adalimumab reference product (Humira®) in the treatment of active rheumatoid arthritis
Safety of adalimumab biosimilar MSB11022 (acetate-buffered formulation) in patients with moderately-to-severely active rheumatoid arthritis
Review of Adalimumab Biosimilar SB5 in Immune-Mediated Inflammatory Diseases
Demonstration of Functional Similarity of Proposed Biosimilar ABP 501 to Adalimumab
AVT02: An Adalimumab Biosimilar
Review of Biosimilar Trials and Data on Adalimumab in Rheumatoid Arthritis
Correction to: AVT02: An Adalimumab Biosimilar
Real-Life Tolerability and Effectiveness of Adalimumab Biosimilar in Rheumatoid Arthritis: ASPIRE Registry Data
Demonstration of Physicochemical and Functional Similarity of Biosimilar Adalimumab-aqvh to Adalimumab
Long-term efficacy, safety, and immunogenicity of the adalimumab biosimilar, PF-06410293, in patients with rheumatoid arthritis after switching from reference adalimumab (Humira®) or continuing biosimilar therapy: week 52–92 data from a randomized, double-blind, phase 3 trial
Adalimumab and anti-adalimumab LISA-TRACKER immunoassays performance criteria for therapeutic drug monitoring of adalimumab-amgen biosimilar (ABP501)
Consistency of Product Quality for SB5, an Adalimumab Biosimilar
A comparative clinical study of PF-06410293, a candidate adalimumab biosimilar, and adalimumab reference product (Humira®) in the treatment of active rheumatoid arthritis
Safety of adalimumab biosimilar MSB11022 (acetate-buffered formulation) in patients with moderately-to-severely active rheumatoid arthritis
Review of Adalimumab Biosimilar SB5 in Immune-Mediated Inflammatory Diseases
Demonstration of Functional Similarity of Proposed Biosimilar ABP 501 to Adalimumab
AVT02: An Adalimumab Biosimilar
Review of Biosimilar Trials and Data on Adalimumab in Rheumatoid Arthritis
Correction to: AVT02: An Adalimumab Biosimilar
Real-Life Tolerability and Effectiveness of Adalimumab Biosimilar in Rheumatoid Arthritis: ASPIRE Registry Data
Demonstration of Physicochemical and Functional Similarity of Biosimilar Adalimumab-aqvh to Adalimumab
Long-term efficacy, safety, and immunogenicity of the adalimumab biosimilar, PF-06410293, in patients with rheumatoid arthritis after switching from reference adalimumab (Humira®) or continuing biosimilar therapy: week 52–92 data from a randomized, double-blind, phase 3 trial
Adalimumab and anti-adalimumab LISA-TRACKER immunoassays performance criteria for therapeutic drug monitoring of adalimumab-amgen biosimilar (ABP501)
Consistency of Product Quality for SB5, an Adalimumab Biosimilar
A comparative clinical study of PF-06410293, a candidate adalimumab biosimilar, and adalimumab reference product (Humira®) in the treatment of active rheumatoid arthritis
Safety of adalimumab biosimilar MSB11022 (acetate-buffered formulation) in patients with moderately-to-severely active rheumatoid arthritis
Review of Adalimumab Biosimilar SB5 in Immune-Mediated Inflammatory Diseases